|
Pronunciation |
|
(men
oh TROE
pins) |
|
|
U.S. Brand
Names |
|
Humegon™; Pergonal®;
Repronex® |
|
|
Generic
Available |
|
No |
|
|
Pharmacological Index |
|
Gonadotropin; Ovulation Stimulator |
|
|
Use |
|
Sequentially with hCG to induce ovulation and pregnancy in the infertile
woman with functional anovulation or in patients who have previously received
pituitary suppression; used with hCG in men to stimulate spermatogenesis in
those with primary hypogonadotropic hypogonadism |
|
|
Pregnancy Risk
Factor |
|
X |
|
|
Contraindications |
|
Primary ovarian failure, overt thyroid and adrenal dysfunction, abnormal
bleeding, pregnancy, men with normal urinary gonadotropin concentrations,
elevated gonadotropin levels indicating primary testicular
failure |
|
|
Warnings/Precautions |
|
Advise patient of frequency and potential hazards of multiple pregnancy; to
minimize the hazard of abnormal ovarian enlargement, use the lowest possible
dose |
|
|
Adverse
Reactions |
|
Male:
>10%: Endocrine & metabolic: Gynecomastia
1% to 10%: Erythrocytosis (shortness of breath, dizziness, anorexia, syncope,
epistaxis)
Female:
>10%:
Endocrine & metabolic: Ovarian enlargement
Gastrointestinal: Abdominal distention
Local: Pain/rash at injection site
1% to 10%: Ovarian hyperstimulation syndrome
<1%: Thromboembolism, pain, febrile reactions |
|
|
Overdosage/Toxicology |
|
Symptoms of overdose include ovarian hyperstimulation |
|
|
Drug
Interactions |
|
Clomiphene may amount
of HMG needed to induce
ovulation (Gonadorelin, Factrel®) should not be used with
drugs that stimulate ovulation |
|
|
Stability |
|
Lyophilized powder may be refrigerated or stored at room temperature; after
reconstitution inject immediately, discard any unused
portion |
|
|
Mechanism of
Action |
|
Actions occur as a result of both follicle stimulating hormone (FSH) effects
and luteinizing hormone (LH) effects; menotropins stimulate the development and
maturation of the ovarian follicle (FSH), cause ovulation (LH), and stimulate
the development of the corpus luteum (LH); in males it stimulates
spermatogenesis (LH) |
|
|
Pharmacodynamics/Kinetics |
|
Elimination: ~10% of dose is excreted in the urine
unchanged |
|
|
Usual Dosage |
|
Adults: I.M.:
Female: 1 ampul/day (75 units of FSH and LH) for 9-12 days followed by 10,000
units hCG 1 day after the last dose; repeated at least twice at same level
before increasing dosage to 2 ampuls (150 units FSH/150 units LH)
Repronex®: I.M., S.C.:
Infertile patients with oligo-anovulation: Initial: 150 int. units daily for
the first 5 days of treatment. Adjustments should not be made more frequently
than once every 2 days and should not exceed 75-150 int. units per adjustment.
Maximum daily dose should not exceed 450 int. units and dosing beyond 12 days is
not recommended. If patient's response to Repronex® is
appropriate, hCG 5000-10,000 units should be given one day following the last
dose of Repronex®.
Assisted reproductive technologies: Initial (in patients who have received
GnRH agonist or antagonist pituitary suppression): 225 int. units; adjustments
in dose should not be made more frequently than once every 2 days and should not
exceed more than 75-50 int. units per adjustment. The maximum daily doses of
Repronex® given should not exceed 450 int. units and
dosing beyond 12 days is not recommended. Once adequate follicular development
is evident, hCG (5000-10,000 units) should be administered to induce final
follicular maturation in preparation for oocyte retrieval. |
|
|
Administration |
|
I.M. or S.C. (Repronex® ONLY) administration. The lower
abdomen (alternating sides) should be used for subcutaneous
administration. |
|
|
Mental Health: Effects
on Mental Status |
|
None reported |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Self injection: Follow prescriber's recommended schedule for injections.
Multiple ovulations resulting in multiple pregnancies have been reported. Male
infertility and/or breast enlargement may occur. Report pain at injection site;
enlarged breasts (male); difficulty breathing; nosebleeds; acute abdominal
discomfort; or fever, pain, redness, or swelling of calves. |
|
|
Dosage Forms |
|
Injection:
Follicle stimulating hormone activity 150 units and luteinizing hormone
activity 150 units per 2 mL ampul
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|